[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054898":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":12,"responsibleParty":7,"collaborators":7,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":30,"acronym":7,"eligibilityCriteria":31,"healthyVolunteers":28,"sex":32,"minAge":33,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":34,"phases":35,"briefSummary":37,"conditions":38,"keywords":41,"overallStatus":48,"whyStopped":7,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":53,"locationsCount":55},{"fullName":5,"class":6},"NIH AIDS Clinical Trials Information Service","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Atovaquone",[13],{"facility":14,"status":7,"city":15,"state":16,"zip":17,"country":18,"countryCode":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":7},"Glaxo Wellcome Inc","Research Triangle Park","North Carolina","27709","United States","US",{"type":21,"coordinates":22},"Point",[23,24],-78.86029,35.89709,{"lat":24,"lon":23},"100054898","an-open-label-uncontrolled-clinical-trial-of-oral-566c80-for-the-treatment-of-patients-with-severe-pcp-who-are-intolerant-andor-unresponsive-to-therapy-with-trimethoprimsulfamethoxazole-and-parenteral-pentamidine-100054898",false,"NCT00001990","An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and\u002For Unresponsive to Therapy With Trimethoprim\u002FSulfamethoxazole and Parenteral Pentamidine","Inclusion Criteria\n\nPatients must have the following:\n\n* Clinical diagnosis of acute severe Pneumocystis carinii pneumonia (PCP).\n* Dose-limiting intolerance to TMP \u002F SMX and parenteral pentamidine.\n* Willingness and ability to give informed consent.\n\nExclusion Criteria\n\nCo-existing Condition:\n\nExcluded:\n\n* Patients with a history of intolerance to 566C80. Patients with the following prior conditions are excluded: History of serious dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug.\n\nRequired:\n\n* Trimethoprim \u002F sulfamethoxazole (TMP\u002FSMX); pentamidine.","ALL","1 Day","INTERVENTIONAL",[36],"NA","To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and\u002For unresponsive to trimethoprim \u002F sulfamethoxazole ( TMX \u002F SMX ); to monitor serious adverse events attributable to 566C80.",[39,40],"Pneumonia, Pneumocystis Carinii","HIV Infections",[42,43,44,45,46,47],"Trimethoprim-Sulfamethoxazole Combination","Pneumonia, Pneumocystis carinii","Pentamidine","Antifungal Agents","Acquired Immunodeficiency Syndrome","atovaquone","COMPLETED","2005-06-23",{"date":51,"type":52},"2005-06-24","ESTIMATED",{"name":54,"class":6},"Glaxo Wellcome",1]